SHSE •
Healthcare •
Biotechnology •
Quote as of 09/14/2026 09:25
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeSHSE
Market Capitalization69,563 mln
Float341 mln
Earnings Date10/30/2026
EPS
10.45
Robust
P / E
10.98
Fair value
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-1.54
Likely manipulated
1-Year Forecast
146
Strong upside
Relative Strength
31
/ 100
Underperforming
Business Description
RemeGen is a biopharmaceutical company based in Yantai, China, that creates and sells biological medicines for patients with autoimmune conditions, cancer, and eye diseases across China and the United States. Its two main products are Telitacicept, used to treat lupus, rheumatoid arthritis, and myasthenia gravis, and Disitamab Vedotin, an antibody-based therapy targeting gastric, bladder, breast, and other cancers. The company also has a broad pipeline of experimental drugs in clinical development, including treatments aimed at a range of solid tumors and conditions driven by abnormal cell growth. Founded in 2008, RemeGen continues to expand its reach and drug portfolio across both Chinese and global markets.
